Stay updated on IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial

Sign up to get notified when there's something new on the IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a new version, changing from v2.14.4 to v2.15.0.
    Difference
    0.9%
    Check dated 2025-04-16T01:35:18.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.3%
    Check dated 2025-04-08T20:09:11.000Z thumbnail image
  4. Check
    22 days ago
    No Change Detected
  5. Check
    58 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    5%
    Check dated 2025-02-24T16:29:24.000Z thumbnail image
  6. Check
    72 days ago
    Change Detected
    Summary
    The page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    5%
    Check dated 2025-02-10T09:14:04.000Z thumbnail image
  7. Check
    80 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.1 to 2.14.2.
    Difference
    0.3%
    Check dated 2025-02-03T04:56:18.000Z thumbnail image
  8. Check
    94 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.0 to 2.14.1.
    Difference
    0.3%
    Check dated 2025-01-19T19:24:35.000Z thumbnail image

Stay in the know with updates to IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial

Enter your email address, and we'll notify you when there's something new on the IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial page.